MENU
JUN 17, 2020 6:00 AM PDT

Rapid Development of Multiplex Serological Assays for COVID-19 Beyond

Sponsored by: LUMINEX
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Senior Field Applications Scientist, Luminex
    Biography
      Dr. Angeloni has over 25 years of research and industry experience with the development of a wide variety of biochemical, genetic, proteomic, immunology, microscopy, cellular and molecular biology assays. These technologies were applied to studying genetic and environmental factors contributing to the susceptibility or resistance to a number of infectious and non-infectious diseases. This includes studies on disease mechanisms or treatments in the areas of endocrinology, cancer, obesity, diabetes and the development of DNA vaccines. These research efforts employed cellular, mouse and non-human primate model systems. This diversified experience has been applied to developing and supporting commercial applications for cellular genetic engineering, bioinformatic data analysis as well the development of genomic and proteomic assay platforms for research and diagnostics. This experience is now available for supporting the research efforts of Luminex customers for all their custom assay needs.
    • Assistant Professor in Pathology and Laboratory Medicine at the University of Rochester Medical Center in Rochester NY
      Biography
        Nicole Pecora got her MD and PhD from Case Western Reserve University in Cleveland Ohio where she focused on host/pathogen interactions in Tuberculosis. She completed her residency in clinical pathology and fellowship in medical microbiology at Brigham and Women's Hospital in Boston MA. She is currently an Assistant Professor in Pathology and Laboratory Medicine at the University of Rochester Medical Center in Rochester NY where she is also the Associate Director of Clinical Microbiology. In this role she has overseen both molecular and serological diagnostics for COVID-19.

      Abstract

      Since the outbreak of the Covid-19 pandemic, the development of diagnostics for both the virus (molecular) and the host immune response (serological) has become essential for monitoring the spread of the disease, monitoring those that have been infected (often with little or no symptoms) and monitoring the recovery of survivors.  In the current climate, with a new disease and quickly released products, sensitivity and specificity are major concerns for all of these diagnostic modalities.

      The immune response to SARS-CoV2 is still poorly understood.  It is unknown which antigens (if any) may correlate with protective immunity.  Most current serological assays are limited in their ability to monitor and distinguish multiple markers in a single patient sample.  With the importance of measuring the antibody responses of patients exposed to Covid-19, the need for an accurate, rapid assay that is versatile enough to respond to our quickly evolving knowledge of this illness is in high demand.

      This presentation describes the development of a rapid multiplex serological assay.  Antibody responses to the SARS-CoV-2 Spike (S), receptor binding domain (RBD) and nucleocapsid (NP) antigens are measured in a 96 well format with as little as 10ul of patient serum.  A full 96 well plate with samples and controls can be processed in about 45 minutes with a read time of around 20 minutes. This assay was found to be both highly sensitive (92% by day 16) and specific (100%).

      Learning Objectives:

      1. Understand the components of a microsphere multiplex immunoassay

      2. Understand how a multiplexed assay can answer questions about the serological response to SARS-CoV-2


      Show Resources
      You May Also Like
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      C.E. CREDITS
      This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
      JUN 17, 2020 1:30 PM PDT
      C.E. CREDITS
      JUN 17, 2020 1:30 PM PDT
      Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
      MAY 08, 2020 10:00 AM PDT
      C.E. CREDITS
      MAY 08, 2020 10:00 AM PDT
      DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
      LIVE NOW!
      C.E. CREDITS
      LIVE NOW!
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      NOV 16, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      Loading Comments...
      Show Resources
      Attendees
      • See more